Chardan Capital Weighs in on Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for Metagenomi in a research note issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($1.47) for the year. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi’s FY2026 earnings at ($0.76) EPS.

Metagenomi (NASDAQ:MGX) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The company had revenue of $9.61 million for the quarter, compared to the consensus estimate of $13.18 million. Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. During the same quarter last year, the company posted ($20.05) EPS.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company dropped their price objective on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 18th. HC Wainwright upped their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Metagenomi has an average rating of “Moderate Buy” and an average price target of $14.40.

Metagenomi Stock Performance

NASDAQ MGX opened at $1.48 on Thursday. The company has a market capitalization of $55.33 million and a PE ratio of -0.56. Metagenomi has a 52-week low of $1.46 and a 52-week high of $10.94. The company has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $2.44.

Hedge Funds Weigh In On Metagenomi

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after acquiring an additional 7,256 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Metagenomi during the 3rd quarter valued at about $82,000. Geode Capital Management LLC boosted its stake in shares of Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after purchasing an additional 173,796 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Metagenomi during the fourth quarter valued at about $1,268,000. Finally, Rhumbline Advisers raised its stake in Metagenomi by 123.3% in the fourth quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock worth $43,000 after buying an additional 6,626 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.